Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740890 · ClinicalTrials.gov registry record · Phase 4
Exercise and Olanzapine-samidorphan
A Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06740890: Recruiting Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder, sponsored by New York State Psychiatric Institute.
NCT06740890 is a Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 30 participants, below the 172-participant average among 103 other Schizoaffective Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06740890, a Phase 4 study of Schizoaffective Disorder and Schizophenia Disorder, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
Primary Outcome
Body weight
Conditions Studied
Interventions
- DRUG Olanzapine-samidorphan + exercise
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT06740890 shows while recruiting
NCT06740890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 172-participant average among 103 other Schizoaffective Disorder trials with a reported enrollment target (83% lower).
The record links to 4 conditions, with Schizoaffective Disorder appearing as the primary indexed condition, and to 1 intervention - of which Olanzapine-samidorphan + exercise is the first listed.
NCT06740890 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06740890 about?
NCT06740890 is a clinical study titled "Exercise and Olanzapine-samidorphan". This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
What is the current status of trial NCT06740890?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-06-26. Estimated completion is 2027-04.
What conditions does trial NCT06740890 study?
This clinical trial studies the following conditions: Schizoaffective Disorder, Schizophenia Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS.
What interventions are being tested in trial NCT06740890?
The interventions under investigation include: Olanzapine-samidorphan + exercise (DRUG).
Who is sponsoring clinical trial NCT06740890?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740890 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizoaffective Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06740890's enrollment target sits among peer trials
30 82nd of 103 higher than 18 of 103 other Schizoaffective Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizoaffective Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anticholinergic Deprescription in Schizophrenia
RECRUITING · Phase 4
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI